Legend Biotech Quarterly Income Statements Chart
Quarterly
|
Annual
Legend Biotech Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2022-12-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| revenue | ||||||
| license revenue | 12,181 | -12 | 35,172 | 15,115 | ||
| collaboration revenue | 78,481 | 79,435 | 170,369 | 94,432 | 11,937,000 | |
| other revenue | 3,329 | 41 | 138 | 119 | 34,000 | |
| total revenue | 93,991 | 79,464 | 205,679 | 109,666 | 11,971,000 | |
| collaboration cost of revenue | -49,101 | -32,450 | -111,764 | -68,285 | -16,939,000 | |
| cost of license and other revenue | -5,638 | |||||
| other income and gains | 64,091 | 8,314 | 49,812 | 20,994 | 1,856,000 | |
| research and development expenses | -100,964 | -105,683 | -276,535 | -180,680 | -68,827,000 | |
| administrative expenses | -31,929 | -28,707 | -78,062 | -49,958 | -18,050,000 | |
| selling and distribution expenses | -24,223 | -33,677 | -60,481 | -39,383 | -27,440,000 | |
| other incomes | -540 | -28,253 | -231 | -7,117 | -8,099,000 | |
| fair value gain of warrant liability | ||||||
| finance costs | -5,475 | -5,820 | -15,974 | -10,298 | -1,643,000 | |
| income before tax | -59,788 | -146,812 | -373,306 | -310,811 | -193,071,000 | |
| income tax expense | -5 | -418 | -157,000 | |||
| loss for the period | -59,793 | -93,359 | -373,436 | -311,229 | -193,228,000 | |
| attributable to: | ||||||
| ordinary equity holders of the parent | -59,793 | -144,818 | -373,436 | -311,229 | -193,228,000 | |
| loss per share attributable to ordinary equity holders of the parent | ||||||
| basic | -0.16 | -0.4 | -1.07 | -0.91 | ||
| diluted | -0.16 | -0.4 | -1.07 | -0.91 | ||
| other comprehensive (loss)/ income | ||||||
| other comprehensive income that may be reclassified to profit or loss in subsequent periods: | ||||||
| exchange differences: | ||||||
| exchange differences on translation of foreign operations | -47,993 | 43,338 | -13,705 | 6,537 | ||
| net other comprehensive (loss)/ income that may be reclassified to profit or loss in subsequent periods | -47,993 | -3,426.25 | -13,705 | |||
| other comprehensive (loss)/ income for the period, net of tax | -47,993 | -3,426.25 | -13,705 | |||
| total comprehensive loss for the period | -107,786 | -96,785.25 | -387,141 | -304,692 | ||
| fair value gain/(loss) of warrant liability | -21,437.5 | -85,750 | ||||
| income tax benefit/ | 1,994 | -130 | ||||
| other comprehensive income | ||||||
| fair value loss of warrant liability | -85,750 | |||||
| net other comprehensive income that may be reclassified to profit or loss in subsequent periods | 6,537 | |||||
| other comprehensive income for the period, net of tax | 6,537 | |||||
| fair value gain/loss of warrant liability | -65,900,000 | |||||
| loss per share attributable to ordinary equity holders of the parent: | ||||||
| ordinary shares – basic | -0.62 | |||||
| ordinary shares – diluted | -0.62 | |||||
| shares used in loss per share computation: |
We provide you with 20 years income statements for Legend Biotech stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Legend Biotech stock. Explore the full financial landscape of Legend Biotech stock with our expertly curated income statements.
The information provided in this report about Legend Biotech stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.